Issue No. 9 · Week of October 12, 2026
Tariffs dominated this week. The BD deal shows that Section 232 device tariffs are being used to pull production onshore, and the pharmaceutical rollout shows that exemptions favor companies with U.S. investment. If you ship into the U.S. without local production, now is the time to model your landed costs and organize your exemption and country of origin documentation.
Hospitals and Health Systems
CMS cuts Medicare payments to 2,334 hospitals under the FY2027 readmissions program
About 80 percent of the hospitals evaluated by the Centers for Medicare and Medicaid Services face payment cuts effective October 1. On top of thin margins, that makes hospitals more selective on capital and more price sensitive on consumables. Expect longer capital sales cycles and stronger demands for evidence of cost savings or better outcomes.
Source: Becker’s Hospital Review
Hospital merger wave closes the quarter: UPMC enters Ohio, WVU Health reaches 30 hospitals
UPMC completed its purchase of Trinity Health System in Ohio, WVU Health System added five hospitals with an $800 million modernization pledge, and Parkview, MaineHealth and Tampa General also closed deals. A change of ownership typically moves purchasing onto the new parent’s group purchasing organization (GPO) and contracts, so suppliers should confirm which agreements now apply.
Source: Becker’s Hospital Review
Regulatory: FDA and Health Canada
FDA issues draft guidance on premarket submissions for robotically assisted surgical devices
The 50 page draft covers system stability and latency, motion control, software, cybersecurity, sterilization, clinical data, labeling and training. Comments are due November 24, and FDA will hold a public workshop December 2 to 3 on autonomous and remote capabilities. Makers of surgical robotics or accessories should review the software and cybersecurity expectations and consider commenting.
Source: MedTech Dive
BD Alaris pump infusion sets recall classified Class I, FDA’s most serious category
Testing showed that set performance at low flow rates (under 1 mL/h) was significantly overestimated, risking under or over infusion and delayed occlusion alarms, with the greatest danger to neonates and critically ill patients. Makers of infusion sets and tubing should expect hospitals and GPOs to ask for low flow accuracy data and occlusion alarm test results.
Source: FDA
FDA device center publishes its FY2027 guidance agenda, led by AI, change control plans and robotic surgery
The Center for Devices and Radiological Health plans 11 final and 3 draft guidances, including AI enabled device lifecycle, predetermined change control plans and quality management system information for premarket reviews. Comments are open until November 30. Final guidance will set what FDA expects in 510(k) and premarket approval files.
Source: RAPS
Comments on FDA’s generative AI device framework close October 19
FDA asked for input on risk assessment, premarket evaluation and postmarket monitoring for generative AI enabled devices, under docket FDA-2026-N-7874. Manufacturers with AI features have one week left to shape the expectations that will apply to their 510(k) and De Novo submissions.
Source: FDA
Health Canada device shortage and discontinuation reporting rules take effect June 17, 2027
Amended rules change how manufacturers, importers and distributors report device shortages and discontinuations. Foreign manufacturers licensed in Canada should use the coming months to update procedures, supply forecasts and documentation, and to line up the Canadian importers or distributors who share the reporting duty.
Source: Fasken
Import, Customs and Trade
BD wins future Section 232 tariff relief for U.S. investment as device tariffs loom by year end
Becton Dickinson will use U.S. steel for needles sold in the U.S. and expects about 80 percent of its U.S. supply to be domestic, in exchange for relief that depends on undisclosed milestones. Reports differ on the investment figure ($3 billion in one, $19 billion in another), and the President says strong device tariffs are coming by year end. Foreign manufacturers should model landed cost scenarios now and ask distributors how they will treat imported product.
Source: MedTech Dive
Small biotechs struggle to get exemptions as the broad Section 232 pharmaceutical tariff takes effect
Smaller companies report little clear guidance on how to qualify for relief, which tends to favor firms with U.S. investment commitments. The separate Section 232 device probe is still pending. A foreign device maker without U.S. production should plan its exemption documentation early.
Source: STAT News
Court of International Trade hears challenge to Section 301 tariffs covering 99.4 percent of U.S. imports
A three judge panel heard arguments from small businesses and 25 states that the broad duties exceed presidential authority. No ruling had been reported as of this writing. A decision could change duty rates on imported devices and components and open refund questions for importers of record, so keep entry records and country of origin documentation in order.
Source: CNBC
Also Noted
USTR amends China Section 301 product exclusion
USTR amended one China Section 301 product exclusion (statistical number 8479.90.9591) to match new tariff reporting categories. Confirm your HTS codes still map to any exclusion you rely on.
Source: Federal Register
Ascension rethinks payer contracting amid Medicare Advantage exits
Ascension is rethinking payer contracting amid Medicare Advantage exits and rising denials, with care shifting to ambulatory sites. Products suited to outpatient and surgery center settings stand to benefit.
Source: Becker’s Hospital Review
Key Takeaways for Medical Device Manufacturers
This week’s developments highlight the growing importance of tariff planning for foreign medical device manufacturers. With Section 232 device tariffs still under consideration and U.S. investment influencing potential relief, manufacturers should evaluate landed costs, country of origin documentation and exemption requirements before changes affect their import operations.
FDA’s evolving expectations for surgical robotics, AI enabled devices and infusion system performance also reinforce the need for strong regulatory documentation and product testing. Meanwhile, hospital payment reductions and consolidation may increase purchasing scrutiny, making clinical outcomes and cost effectiveness increasingly important to supplier relationships.
Questions About U.S. or Canadian Market Access?
Dawa Medical supports foreign medical device manufacturers entering the U.S. market as U.S. Agent, FDA Initial Importer and Importer of Record, with 3PL warehousing and regulatory compliance support. Through TB Medical Inc., manufacturers can also access Canadian importation and distribution support.
About The Access Brief: The Access Brief summarizes publicly reported news affecting medical device manufacturers selling into the United States and Canada and reflects Dawa Medical’s own understanding. It is not legal, regulatory or binding advice, and formal advice should come from qualified counsel or a specialist consultant.
